Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06854081 · ClinicalTrials.gov registry record

EluPro Antibiotic-Eluting BioEnvelope Registry

A clinical trial of Cardiac Arrhythmias, sponsored by Elutia.

Recruiting
Registry status
100
Enrollment target
4
Study locations

NCT06854081 is a study of Cardiac Arrhythmias that is actively recruiting participants, run by Elutia. The registered enrollment target is 100 participants, below the 522-participant average among 5 other Cardiac Arrhythmias trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06854081, a study of Cardiac Arrhythmias, is actively recruiting participants, sponsored by Elutia.

RECRUITING
Registry status
100 participants
Enrollment target
4
Study locations

Study Summary

A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation

Conditions Studied

Interventions

  • COMBINATION_PRODUCT EluPro Antibiotic-Eluting BioEnvelope

Study Locations (4)

California

  • UC San Diego Health - La Jolla

Florida

  • Tallahassee Research Institute - Tallahassee

Massachusetts

  • Brigham & Women's Hospital - Boston

Pennsylvania

  • Penn Presbyterian Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-17
Est. Completion 2026-12

Sponsor

Elutia

10 total trials

What the Registry Record Tells You About NCT06854081

The ClinicalTrials.gov registry entry for NCT06854081 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 522-participant average among 5 other Cardiac Arrhythmias trials with a reported enrollment target (81% lower). The listed sponsor is Elutia, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiac Arrhythmias appearing as the primary indexed condition, and to 1 intervention - of which EluPro Antibiotic-Eluting BioEnvelope is the first listed.

NCT06854081 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06854081 about?

NCT06854081 is a clinical study titled "EluPro Antibiotic-Eluting BioEnvelope Registry". A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation

What is the current status of trial NCT06854081?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-04-17. Estimated completion is 2026-12.

What conditions does trial NCT06854081 study?

This clinical trial studies the following conditions: Cardiac Arrhythmias.

What interventions are being tested in trial NCT06854081?

The interventions under investigation include: EluPro Antibiotic-Eluting BioEnvelope (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06854081?

This trial is sponsored by Elutia, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06854081 being conducted?

This trial has 4 study locations across California, Florida, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiac Arrhythmias

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.